» Articles » PMID: 30333177

Acute Infection and Subsequent Subclinical Reactivation of Herpes Simplex Virus 2 After Vaginal Inoculation of Rhesus Macaques

Abstract

Herpes simplex virus 2 (HSV-2) is a common sexually transmitted infection with a highly variable clinical course. Many infections quickly become subclinical, with episodes of spontaneous virus reactivation. To study host-HSV-2 interactions, an animal model of subclinical HSV-2 infection is needed. In an effort to develop a relevant model, rhesus macaques (RM) were inoculated intravaginally with two or three HSV-2 strains (186, 333, and/or G) at a total dose of 1 × 10 PFU of HSV-2 per animal. Infectious HSV-2 and HSV-2 DNA were consistently shed in vaginal swabs for the first 7 to 14 days after each inoculation. Proteins associated with wound healing, innate immunity, and inflammation were significantly increased in cervical secretions immediately after HSV-2 inoculation. There was histologic evidence of acute herpesvirus pathology, including acantholysis in the squamous epithelium and ballooning degeneration of and intranuclear inclusion bodies in epithelial cells, with HSV antigen in mucosal epithelial cells and keratinocytes. Further, an intense inflammatory infiltrate was found in the cervix and vulva. Evidence of latent infection and reactivation was demonstrated by the detection of spontaneous HSV-2 shedding post-acute inoculation (10 to 10 DNA copies/swab) in 80% of RM. Further, HSV-2 DNA was detected in ganglia in most necropsied animals. HSV-2-specifc T-cell responses were detected in all animals, although antibodies to HSV-2 were detected in only 30% of the animals. Thus, HSV-2 infection of RM recapitulates many of the key features of subclinical HSV-2 infection in women but seems to be more limited, as virus shedding was undetectable more than 40 days after the last virus inoculation. Herpes simplex virus 2 (HSV-2) infects nearly 500 million persons globally, with an estimated 21 million incident cases each year, making it one of the most common sexually transmitted infections (STIs). HSV-2 is associated with increased human immunodeficiency virus type 1 (HIV-1) acquisition, and this risk does not decline with the use of antiherpes drugs. As initial acquisition of both HIV and HSV-2 infections is subclinical, study of the initial molecular interactions of the two agents requires an animal model. We found that HSV-2 can infect RM after vaginal inoculation, establish latency in the nervous system, and spontaneously reactivate; these features mimic some of the key features of HSV-2 infection in women. RM may provide an animal model to develop strategies to prevent HSV-2 acquisition and reactivation.

Citing Articles

A nonhuman primate model for genital herpes simplex virus 2 infection that results in vaginal vesicular lesions, virus shedding, and seroconversion.

Wang K, Jordan T, Dowdell K, Herbert R, Moore I, Koelle D PLoS Pathog. 2024; 20(9):e1012477.

PMID: 39226323 PMC: 11371218. DOI: 10.1371/journal.ppat.1012477.


Primate Simplexviruses Differ in Tropism for Macaque Cells.

Hofmann-Winkler H, Siregar A, Esiyok N, Rodriguez-Polo I, Gartner S, Behr R Microorganisms. 2023; 11(1).

PMID: 36677317 PMC: 9864361. DOI: 10.3390/microorganisms11010026.


The predictive value of macaque models of preexposure prophylaxis for HIV prevention.

Garcia-Lerma J, McNicholl J, Heneine W Curr Opin HIV AIDS. 2022; 17(4):179-185.

PMID: 35762371 PMC: 10966437. DOI: 10.1097/COH.0000000000000738.


HSV-2-Specific Human Female Reproductive Tract Tissue Resident Memory T Cells Recognize Diverse HSV Antigens.

Koelle D, Dong L, Jing L, Laing K, Zhu J, Jin L Front Immunol. 2022; 13:867962.

PMID: 35432373 PMC: 9009524. DOI: 10.3389/fimmu.2022.867962.


The Chinese Herbal Prescription JieZe-1 Inhibits Membrane Fusion and the Toll-like Receptor Signaling Pathway in a Genital Herpes Mouse Model.

Duan Q, Liu T, Huang C, Shao Q, Ma Y, Wang W Front Pharmacol. 2021; 12:707695.

PMID: 34630083 PMC: 8497740. DOI: 10.3389/fphar.2021.707695.


References
1.
Johnston C, Koelle D, Wald A . Current status and prospects for development of an HSV vaccine. Vaccine. 2013; 32(14):1553-60. PMC: 4106293. DOI: 10.1016/j.vaccine.2013.08.066. View

2.
NAIB Z, Nahmias A, Josey W . Cytology and histopathology of cervical herpes simplex infection. Cancer. 1966; 19(7):1026-31. DOI: 10.1002/1097-0142(196607)19:7<1026::aid-cncr2820190718>3.0.co;2-#. View

3.
Looker K, Magaret A, Turner K, Vickerman P, Gottlieb S, Newman L . Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS One. 2015; 10(1):e114989. PMC: 4301914. DOI: 10.1371/journal.pone.0114989. View

4.
Johnston C, Corey L . Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding. Clin Microbiol Rev. 2015; 29(1):149-61. PMC: 4771215. DOI: 10.1128/CMR.00043-15. View

5.
Jing L, Chong T, Byrd B, McClurkan C, Huang J, Story B . Dominance and diversity in the primary human CD4 T cell response to replication-competent vaccinia virus. J Immunol. 2007; 178(10):6374-86. DOI: 10.4049/jimmunol.178.10.6374. View